Explore
Validate
Learn
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-56366 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- YRDC Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: ASSLNVEEFQ DLWPQLSLVI DGGQIGDGQS PECRLGSTVV DLSVPGKFGI IRPGCALEST TAILQQKYGL LP
- Concentration
- 0.2 mg/mL
Submitted references Defects in t(6)A tRNA modification due to GON7 and YRDC mutations lead to Galloway-Mowat syndrome.
Arrondel C, Missoury S, Snoek R, Patat J, Menara G, Collinet B, Liger D, Durand D, Gribouval O, Boyer O, Buscara L, Martin G, Machuca E, Nevo F, Lescop E, Braun DA, Boschat AC, Sanquer S, Guerrera IC, Revy P, Parisot M, Masson C, Boddaert N, Charbit M, Decramer S, Novo R, Macher MA, Ranchin B, Bacchetta J, Laurent A, Collardeau-Frachon S, van Eerde AM, Hildebrandt F, Magen D, Antignac C, van Tilbeurgh H, Mollet G
Nature communications 2019 Sep 3;10(1):3967
Nature communications 2019 Sep 3;10(1):3967
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of YRDC in human cell line U-2 OS shows positivity in mitochondria. Samples were probed using a YRDC Polyclonal Antibody (Product # PA5-56366).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of YRDC in human pancreas shows strong cytoplasmic positivity in exocrine glandular cells and Islet cells. Samples were probed using a YRDC Polyclonal Antibody (Product # PA5-56366).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 Effects of YRDC and GON7 mutations on t 6 A biosynthesis. a Evaluation of fitness of Deltasua5 yeast strains expressing human YRDC variants (spots are from 10-fold serial dilutions of cell suspensions at OD 600nm = 0.5, and three independent clones were evaluated) and b western blot analysis on total protein extracts from Deltasua5 yeast cells expressing human YRDC variants using anti-hYRDC antibody. c , d Mass spectrometry (LC-MS/MS) quantification of t 6 A modification in total tRNAs extracted from Deltasua5 yeast cells expressing human YRDC variants ( c ) (mean +- s.e.m. of two independent LC-MS/MS experiments (technical replicates), each measuring samples from three independent yeast transformants; one-way ANOVA ( F (5,28) = 269.4, p < 0.0001), Dunnett's multiple comparisons test, *** p = 0.0008, **** p < 0.0001) and from cultured primary skin fibroblasts from controls (two unaffected individuals) and affected individuals with either the p.Tyr7* GON7 mutation (two individuals), or the YRDC mutations (three individuals) or with the p.Arg352Gln OSGEP mutation in the homozygous state (individual < > described in Braun et al. 13 ) ( d ) (mean +- s.e.m. of two independent LC-MS/MS experiments (technical replicates), each measuring samples from three independent cell culture experiments; one-way ANOVA ( F (3,44) = 6.446, p < 0.001), Dunnett's multiple comparisons test, n.s. = 0.4894, * p = 0.0169, *** p = 0.008). Source data are provided as a Source Data file
